CN103110718B - A kind of preparation for protecting liver, adjusting blood lipid - Google Patents
A kind of preparation for protecting liver, adjusting blood lipid Download PDFInfo
- Publication number
- CN103110718B CN103110718B CN201310054324.9A CN201310054324A CN103110718B CN 103110718 B CN103110718 B CN 103110718B CN 201310054324 A CN201310054324 A CN 201310054324A CN 103110718 B CN103110718 B CN 103110718B
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- preparation
- meal
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
It is a kind of to adjust metabolism, protection liver, the preparation for preventing and treating cardiovascular and cerebrovascular disease; using 400~500 parts of pueraria lobata, 400~500 parts of Radix Glycyrrhizae, 300~400 parts of cape jasmine, 30~400 parts of Radix Salviae Miltiorrhizae, 60~120 parts of Radix Notoginseng, 40~70 parts of propolis, 30~70 parts of dextrin extracted, mixing; then through particle preparation be made granule or it is filled capsule is made, tablet is made in tabletting.It is recommended that taking daily effective quantity is 4~5g, and in three times, one after each meal, warm water delivery service.The beneficial effects of the present invention are: the activity of superoxide dismutase in human body (SOD), glutathione peroxidase (GSH-PX) can be improved in flavone compound contained in invention formulation; reduce the content of malonaldehyde (MDA) in hepatomicrosome; thus to adjust liver blood circulatory function; it improves liver and absorbs nutrition, metabolism and the ability for removing toxin; it not only can protect liver; reduce hepar damnification; and it can boost metabolism; the accumulation of fat is reduced, cardiovascular and cerebrovascular disease is prevented and treated.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparations, for protecting hepar damnification, adjusting blood lipid.
Background technique
Metabolism is a series of general name of the orderly chemical reactions for sustaining life occurred in organism.These are anti-
Answer process that organism is enabled to grow and breed, keep their structure and make a response to external environment.Metabolism can be with
It is considered as the process that organism constantly carries out exchanges of mass and energy, once the exchange of matter and energy stops, organism
Structure and system will disintegrate.Metabolic disorder is a kind of state of body, is that body the digestion of substance, absorption, excretion occurs
Pathologic, the state of uncoordinated unbalanced supply-demand.Metabolic disorder can cause many symptoms, such as fatty liver, hyperlipidemia, glycosuria
Disease etc..Liver is the metabolism factory of human body, is the vitals of human metabolism, there is deoxidation inside body, stores liver
The effects of sugar, the synthesis of secreted protein.Liver is very fragile, it is easy to which, by the damage of various virulence factors, common leads
The reason of causing hepatic lesion has following a few classes: infection, drug hepatitis, alcoholic hepatitis, oneself immunity hepatitis etc..Liver is once
There is fat deposition, often implies that fat will start to deposit in whole body, the metabolism of lipid, sugar starts to get muddled, glycosuria
Disease, cardiovascular and cerebrovascular disease etc. are more likely to come one after another.The abnormal especially adipose metabolism of liver function is abnormal, will lead to blood lipid
It increases, lecithin synthesis reduction, dramatically increases the illness rate of cardiovascular and cerebrovascular diseases, there is scholar to think, cardiovascular and cerebrovascular disease is mainly
The result of adipose metabolism exception.
Summary of the invention
The present invention provides a kind of preparation for protecting liver, adjusting blood lipid, can protect hepar damnification, adjusts liver generation
It thanks, prevent and treat cardiovascular and cerebrovascular disease.
The technical scheme adopted by the invention is that: it uses pueraria lobata, Radix Glycyrrhizae, cape jasmine, Radix Salviae Miltiorrhizae, Radix Notoginseng, propolis, dextrin for original
Material, by following quality proportionings: 400~500 parts of pueraria lobata, 400~500 parts of Radix Glycyrrhizae, 300~400 parts of cape jasmine, 30~400 parts of Radix Salviae Miltiorrhizae,
60~120 parts of Radix Notoginseng, 40~70 parts of propolis, 30~70 parts of dextrin be made.The preparation process of invention formulation are as follows: take formula ratio
Pueraria lobata, Radix Glycyrrhizae, cape jasmine, Radix Salviae Miltiorrhizae are placed in multi-function extractor, the water immersion of 8 times of dosing material amounts 30 minutes, and heating extraction 2 times,
1.5 hours every time, filtering (filter material is 80 mesh nylon cloths), filtrate stood 12 hours, supernatant is taken, with plate and frame filter press (filter material
For filter paper) squeezing filtration, collect filtrate.It sets in vacuum concentration pot, being concentrated into relative density is 1.06-1.10 (60 DEG C of heat are surveyed),
Obtain extractum A.Take the propolis of formula ratio set in -4 DEG C or less household freezers freeze after, crushed 20 meshes and obtain coarse powder, set seepage pressure effects
In device, add 95% ethyl alcohol dipped powder about 3cm, after infiltration 24 hours, unlatching equipment, coutroi velocity (0.15L/min), and with
When supplement 95% ethyl alcohol from above, keep extracting liquid level and be higher than 3~4cm of propolis face, when the volume of percolate is equivalent to crude drug
8 times of weight can be to be basically completed, and collect percolate, and after percolate standing sedimentation 12 hours, supernatant centrifugation removes lead (revolving speed
3000 revs/min), the percolate after except lead is recycled into ethyl alcohol using decompression method, and (vacuum degree 0.08MPa, temperature is concentrated
Degree is less than 60 degree) medicinal extract B is obtained to relative density 1.06~1.10 (50 DEG C are surveyed).Merge extractum A and B, be dried in vacuo (vacuum degree:
0.08MPa, temperature 60 C), dry extract is obtained, crushing sieves with 100 mesh sieve.Radix Notoginseng is crushed and is sieved with 100 mesh sieve, with extract powder and paste
Essence is mixed together, then through particle preparation be made granule or it is filled capsule is made, tablet is made in tabletting.
Part of the present invention is mass parts, is the mass units such as microgram commonly used in the art, milligram, gram, kilogram.
It is 4~5g that invention formulation suggestion, which takes daily effective quantity, in three times, one after each meal, warm water delivery service.
The beneficial effects of the present invention are: superoxides in human body can be improved in flavone compound contained in invention formulation
The activity of mutase (SOD), glutathione peroxidase (GSH-PX) reduces the content of malonaldehyde (MDA) in hepatomicrosome,
To improve liver to adjust liver blood circulatory function and absorb nutrition, metabolism and the ability for removing toxin, not only can protect
Liver reduces hepar damnification, and can boost metabolism, and reduces the accumulation of fat, prevents and treats cardiovascular and cerebrovascular disease.
Compound basis:
Pueraria lobata, it is sweet in flavor, pungent, it is mild-natured, enter taste warp, inspires stomach Qi uplink, ascending the clear and descending the turbid.Pueraria lobata containing a variety of flavonoids at
Point, mouse internal superoxide dismutase (SOD), glutathione-peroxidase (GSH-PX), glutathione after drinking
(GSH) abnormal to reduce, Serum MDA (MDA) increases extremely.It, can enhancement of SOD, GSH-PX vigor and GSH after stomach-filling Puerarin
Content reduces MDA content, makes these four indexs close to normal level, illustrate that Puerarin is anti-to body internal oxidition caused by alcohol
There should be apparent antagonism, to have protective effect to the cell of body vitals.Pueraria lobata may additionally facilitate blood circulation, add
The excretion of ethyl alcohol in fast body.Therefore, pueraria lobata have the function of it is good prevention drink caused by chemical damage.Pueraria lobata is also
The power of regeneration of liver cell can be improved, restore normal liver function, promote bile secretion, prevent fat from accumulating in liver.Pueraria lobata
General flavone and Puerarin can improve the oxygen metabolism of cardiac muscle, generate beneficial effect to myocardial metabolism, while can expand blood vessel, reduce
The resistance of blood circulation, therefore myocardial ischemia, artery sclerosis can be prevented and treated etc..The expansion of blood vessel and the proper flow of blood avoid
The formation of thrombus, to avoid the generation of atherosclerosis.In addition pueraria lobata is known as the apparent effect for reducing blood glucose, pueraria lobata institute
The flavone compound contained has effect for reducing blood fat, can reduce serum cholesterol, reduces oily three esters.
Radix Glycyrrhizae has effects that release drug poisoning, food poisoning, interior metabolism product poisoning.Document report, rat are slow
Property or acute alcoholism will lead to hepatic injury, glycyrrhiza preparation and glycyrrhizin have to animal kinds of experiments hepatic injury it is obvious
Protective effect.Licoflavone component gastric infusion can significantly reduce Acute Liver Injury Induced by carbon tetrachloride mice serum paddy third
Mda content increases in transaminase (ALT) and lactic acid dehydrogenase activity raising and liver, also can inhibit Mouse Liver caused by ethyl alcohol
The increase of dirty mda content and the exhaustion of reductive glutathione.Glycyrrhizin or enoxolone can inhibit the increasing of liver fibr tissue
Raw and mitigation interstitial inflammation reaction, histopathologic examination's discovery can also make hepatonecrosis and ballooning degeneration substantially reduced.Radix Glycyrrhizae
Sour diammonium has the function of stronger anti-inflammatory, protection liver plasma membrane and improves liver function.Glycyrrhizic acid has direct suppression to hepatitis B
Production is used, and has inhibiting effect to cell exocrine to hepatitis b virus infected cell surface antigen (HBsAg) in vitro.
Gardenoside has iridoid glycoside activity, can increase the content and glutathione sulfydryl transferase (GST) of liver GSH
Activity, have the function of being quenched free radical, it is anti-oxidant, inhibit tumour and protect liver, capejasmine extract and Gardenoside are to cyt
P450 has selective inhibitory.Research shows that: Gardenia Yellow does not influence the glutamic-pyruvic transaminase of Normal Mouse Serum
(SGPT), the content of glutamic-oxalacetic transaminease (SGOT) and lactic dehydrogenase (LDH) activity and liver malonaldehyde (MDA), but can show
It lands and inhibits the reduction of hepatic injury mouse liver MDA content increased with liver gsh content, and the content and serum of liver GSH
SGPT, SGOT and the height of LDH activity are in inverse variation.Therefore, Gardenia Yellow reduces hepatic injury mice serum SGPT, SGOT
And LDH activity and liver MDA content, liver index, increase liver gsh content mechanism may on the one hand be crocin and
Gardenoside itself not only has a radicals scavenging effect, and can also the free radical scavengers such as rising tune GSH content, protect liver
The integrality of membrane structure and function prevents release of the liver cell to enzyme；Further aspect is that it, which has, adjusts liver particle
The effect of body cyt P450.Cape jasmine decoction and alcohol extract anesthetized cat, big white mouse and rabbit to anesthesia or not, no matter oral or abdominal cavity
Injection, there is persistence antihypertensive effect.
Radix Salviae Miltiorrhizae is a kind of Chinese medicine that promoting blood circulationization is stolen, and can increase capillary network, improves microcirculation, dredges blood in liver and becomes silted up
It is stagnant, and reduce liver cell degree of fibrosis.Radix Salviae Miltiorrhizae also has antioxidation simultaneously, by improving superoxide dismutase in blood
Activity, oxygen radical in scavenger-cell, to protect liver cell.Experimental result shows that Radix Salviae Miltiorrhizae has experimental alcoholic hepatic injury
Significant protective effect, pathology detection and the measurement of liver TG content show that Radix Salviae Miltiorrhizae can reduce hepatic pathology and sexually revise and press down
The raising of the TG of liver cell processed.Prompt Radix Salviae Miltiorrhizae plays a good protective effect to alcoholic liver injury.Its mechanism of action may be
Radix Salviae Miltiorrhizae can reduce the generation of oxygen radical in body, anti-oxidative defense ability in reinforcement, so that improving cell membrane stability, protect
Protect liver cell membrane system.This experiment is that Radix Salviae Miltiorrhizae provides certain experimental basis in terms of the prevention and treatment of alcoholic hepatic injury.Radix Salviae Miltiorrhizae is also
Aorta atheromatous plaque can be made to form area to significantly reduce, reduce serum total cholesterol, triglycerides.Radix Salviae Miltiorrhizae can improve painstaking effort
Guard system reinforces myocardial contractive power, improves cardiac function, do not increase myocardial oxygen consumption；Coronary artery is expanded, myocardial blood flow is increased；
Peripheral blood vessel is expanded, blood flow increases；Improve plasmin activity；Extend bleeding and cotting time, inhibit platelet aggregation, improves blood
Rheological properties.
Radix Notoginseng can release the dense of blood, religion, gather, solidifying state, can obviously increase vascular flow, improve Microcirculation of Liver, subtract
Light hepatic injury.Arasaponin has anti-hepatic fibrosis activity effect, anti-liver lipid peroxidation effect, and protection liver cell effect changes
Kind Microcirculation of Liver, inhibits the pharmacological actions such as tumor cell of liver.Arasaponin has good anti-hepar damnification effect, clinical
For treating hepatitis, glutamic-pyruvic transaminase increase disease etc..Liu Jianlun etc. has studied arasaponin to Hepatic Ischemia/reperfusion Injury
Protective effect.The result shows that malonaldehyde (MDA) content in tissue and blood gradually rises with hepatic ischemia/reperfusion injury and Reperfu- sion,
Moisture is organized, calcium ion content increases, and liver morphology change gradually aggravates.And giving arasaponin in advance can effectively change
Kind changes in histopathology reduces tissue moisture, inhibits calcium ion adverse current and the raising of MDA, i.e. its anti peroxidation of lipid and anti-
Only intracellular calcium excess load is the main mechanism of the protective effect to Hepatic Ischemia/reperfusion Injury.Radix Notoginseng has drop paddy third
The effect for turning glycosides enzyme has facilitation to the recovery of the important cells such as mitochondria, endoplasmic reticulum function and form in liver；To liver
Glycometabolism has facilitation, is conducive to the recovery of hepatic injury.Active constituent in Radix Notoginseng has extensive medicine to cardiovascular system
Reason activity, can reduce myocardial contractive power, and reducing heart rate expands external vessel, reduces the effect of peripheral resistance.
Propolis is the natural gum of honeybee herborization, and is mixed into its maxilla glandular secretion object and beeswax and modulates through honeybee chewing
A kind of colloid substance, due to being rich in flavone compound, unsaturated fatty acid, vitamin E, vitamin C and not in propolis
Come can element zinc, selenium etc., the intracorporal superoxide dismutase activity of small white mouse can be made to significantly improve, had significant anti-oxidant
Effect.Under normal circumstances, have a certain number of free radicals in body, the intracorporal superoxide dismutase of machine, GSH-Px and
The enzymes such as CAT can effectively understand extra free radical, make free radical kept in balance.According to the free basis mechanism of Harman
By the excessive free radical of body can trigger biomembrane unsaturated fatty acid and lipid peroxidation occurs, and generate MDA and lipid peroxidation
Matter, their changes of contents can be with the extent of damage of quantitative response biomembrane such as mitochondrial membrane, cell membrane etc..Excessive free radical
Many cellular components of body can be caused to damage, the especially liver attack that is most subject to free radical causes its that lipid occurs
Peroxidating.Propolis can inhibit the raising of hepatomicrosome MDA content, protect hepatomicrosome by scavenging activated oxygen.Propolis
Not only play the role of removing free radical, also has inhibiting effect to the membrane lipid peroxidatio reaction that free radical causes.Therefore, propolis is
A kind of natural, safety antioxidant, causes hepatic injury to have certain protective effect chemical substance.It is solid to reduce excessively high gallbladder
Alcohol, triglyceride and low-density albumen, increasing high density lipoprotein and the work for preventing vascular thrombosis formation and atherosclerosis
With.
In summary: each ingredient has anti-oxidant, liver protection effect in invention formulation, has to reach to chemical damage
The purpose of assistant protection function, and flavone compound contained therein also has blood fat-reducing blood pressure-decreasing, prevention and treatment cardiovascular and cerebrovascular disease
Effect, the crowd of hepatic injury caused by being applicable in because of a variety of causes applies also for the crowds such as hypertension, hyperlipidemia.
The function of invention formulation:
One, metabolism, liver protecting are adjusted
The activity of superoxide dismutase in human body can be improved in the present invention, may also suppress containing for malonaldehyde in hepatomicrosome
It measures, oxygen radical in scavenger-cell promotes microcirculation in liver, to reach adjusting metabolism, liver-protective effect.
Two, cardiovascular and cerebrovascular disease is prevented and treated
Promote being normally carried out for body lipid metaboli, reduce the permeability of capillary, improve fragility of blood vessels, increases coronary artery stream
Amount reduces cholesterol, triglycerides, prevents vascular thrombosis formation and atherosclerosis, so that reaching reduces blood lipid, the prevention and treatment heart
The effect of cranial vascular disease.
Specific embodiment
The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention..
The present invention will be further described with reference to the examples below:
Embodiment 1: a kind of preparation for protecting liver, adjusting blood lipid, using pueraria lobata 445g, Radix Glycyrrhizae 445g, cape jasmine
335g, Radix Salviae Miltiorrhizae 335g, Radix Notoginseng 90g, propolis 55g, dextrin 50g, extracted, mixing, filling are made capsule 1000, every
0.5g, 3 times a day, 3 tablets each time, one after each meal, warm water delivery service.
Embodiment 2: a kind of preparation for protecting liver, adjusting blood lipid, using pueraria lobata 400g, Radix Glycyrrhizae 410g, cape jasmine
350g, Radix Salviae Miltiorrhizae 350g, Radix Notoginseng 80g, propolis 70g, dextrin 45g, extracted, mixing, particle preparation, tabletting are made 500, tablet,
Every 1g, 3 times a day, 2 tablets once, one after each meal, warm water delivery service.
Embodiment 3: a kind of preparation for protecting liver, adjusting blood lipid, using pueraria lobata 500g, Radix Glycyrrhizae 460g, cape jasmine
300g, Radix Salviae Miltiorrhizae 310g, Radix Notoginseng 100g, propolis 40g, dextrin 55g, extracted, mixing, filling are made capsule 1000, every
0.5g, 3 times a day, 3 tablets each time, one after each meal, warm water delivery service.
Embodiment 4: animal experiment
Using the capsule of the present invention prepared in embodiment 1, test to the liver-protective effect of this product.
1. experimental animal: male SD rat 50 provided by Sichuan institute of antibiotics Experimental Animal Center, weight 180
~220g, quality certification number are as follows: river reality kinoplaszm 2003-005.
2. experimental group and dose design: SD rat is randomly divided into five groups, every group 10, experiment set 375mg/kg,
Tri- dosage groups of 750mg/kg, 1500mg/kg (5,10,20 times that are respectively equivalent to human body recommended amounts) separately set distilled water feminine gender
Control group and 50% ethanol model control group.Liver injury model is caused with ethyl alcohol, dehydrated alcohol concentration is 50% (dilute with distilled water
Release), stomach-filling amount 12ml/kg.bw (dosage of equivalent ethyl alcohol is 6000mg/kg.bw).
3. experimental method: alcoholic liver injury model is used, selects male SD rat 50, point high, medium and low three dosage
Group and a negative control group, a model control group.Tested material, negative control group and mould are given in three daily stomach-fillings of dosage group
Type control group gives distilled water, by 10ml/kg.bw oral stomach-filling once a day, continuously gives 30 days, claims weight twice weekly,
Dosage is adjusted with this.The stomach-filling of model control group and three dosage groups is given to 50% dehydrated alcohol at the end of experiment
12ml/kg.bw, negative control group give distilled water, put to death animal after fasting 16h and take liver, weigh and calculate liver body ratio, take liver
It is dirty that 0.1g/ml liver homogenate is made, triglycerides (TG), malonaldehyde (MDA) and reduced glutathione (GSH) content are surveyed respectively.
4. experimental result
Influence of 4.1 invention formulations to rat body weight, liver weight, liver body ratio, is shown in Table 1.
Influence of 1 invention formulation of table to rat body weight, liver weight, liver body ratio
Seen from table 1, for the original body mass of each dosage group rat of invention formulation compared with negative control group, no conspicuousness is poor
Different (P > 0.05).Groups of animals mid-term weight terminates weight, liver weight and liver body ratio compared with model control group without conspicuousness
Difference (P > 0.05), during entire experiment, growth of animal is good, and continued weight increases, have no animal occur poisoning symptom and
It is dead.
Influence of 4.2 invention formulations to liver homogenate MDA, GSH, TG content, is shown in Table 2.
Influence of 2 invention formulation of table to liver homogenate MDA, GSH, TG content
Note: Δ Δ indicates the P < 0.01 compared with negative control group；* the P < 0.05 compared with model control group is indicated；* P <
0.01。
As can be seen from Table 2, MDA, GSH, TG content have extremely significant property compared with negative control group in model control group liver homogenate
Difference (P < 0.01) shows that the model is successfully, and experimental system is reliable.The GSH of three dosage groups is compared with model control group
It all has conspicuousness and increases (P < 0.05, P < 0.01)；MDA, TG of three dosage groups have decline compared with model control group
Trend and low, high dose group have conspicuousness to reduce (P < 0.05, P < 0.01).The result shows that invention formulation has the work of protect liver
With.
Embodiment 5: human feeding trial
Using the invention formulation prepared in embodiment 1, test to the effect of this product.
1. tested crowd: selecting to meet following standard persons as subject's participation human feeding trial by the principle of voluntariness.
2. subject is included in standard: simple dyslipidemia person；2 serum total cholesterols (TC) are 5.2mmol/ in half a year
L or serum levels of triglyceride (TG) >=1.65mmol/L person；Age 18-65 years old, men and women；Voluntary participation clinical trial is simultaneously signed
Informed consent person.
Subject Exclusion Criteria: the age is in under-18s or over-65s person；Gestation or breast feeding women make the present invention
Agent allergy sufferers；It is associated with the severe totals disease such as angiocarpy, liver, kidney and hemopoietic system, mental patient；Take in a short time with by
The related article of function is tried, the judgement person to result is influenced；The standard of being included in is not met, does not use according to regulations given the test agent, nothing
Method determines effect or data, and umbra does not ring effect or safety judgement person.
3. experimental design and grouping: 100 being met the simple dyslipidemia person for the standard of being included in, by the blood lipid water of subject
It is flat to be randomly divided into 2 groups, test-meal group 50, take invention formulation；Control group 50, take placebo.To test-meal group before test-meal
Balance between the two groups inspection is carried out with control group, wherein age, gender, diet comparing difference have comparable without significant (P > 0.05)
Property.Subject between own control and group using compareing, after comparing test-meal group test-meal front and back and test-meal group and control group test-meal, serum
The situations of change such as total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C).
4. instructions of taking, dosage and time: test-meal group takes invention formulation, and control group takes placebo, everyone every time 3
Grain keeps original life and eating habit constant 3 times a day, during test-meal.Observing time is 30 days.
5. observation index
5.1 efficiency observations: indices in test-meal start and at the end of respectively test it is primary.
5.1.1 total cholesterol (TC) is horizontal and reduces percentage, triglycerides (TG) level and reduces percentage, high density
Lipoprotein cholesterol (HDL-C) level and ascensional range.
5.1.2 effect criterion
Effective: TC reduces > 10%；TG reduces > 15%；HDL-C rises > 0.104mmol/L.
It is invalid: not up to effective standard person.
Observe serum total cholesterol (TC) effective percentage, triglyceride (TG) effective percentage, high-density lipoprotein cholesterol (HDL-
C) efficient and total effective rate (percentage that the effective total number of persons of TC, TG, HDL-C individual event accounts for test-meal number).
5.2 safety observations
5.2.1 general status sign, including spirit, sleep, diet, stool and urine, blood pressure etc..
5.2.2 blood, excrement, routine urianlysis.
5.2.3 Liver and kidney function inspection.
5.2.4 Chest X-rays, electrocardiogram, abdominal B-scan ultrasonography inspection
6. result
Two groups of ages, gender, diet situations compare before 6.1 test-meals
Seen from table 3, two groups of ages, gender before test-meal, there are no significant for blood lipid level difference (P > 0.05), having can
Compare property.
General information compares before 3 test-meal of table
Subject's stool and urine, blood pressure are without exception during 6.2 test-meals, and spirit is normal, and diet situation is consistent with diet, sleeps
It sleeps performance without exception, Chest X-rays, abdominal B-scan ultrasonography, electrocardiogram are existing abnormal before test-meal.
100 subject's red blood cells, white blood cell count(WBC), content of hemoglobin, total serum protein, white egg before and after 6.3 test-meals
White, glutamic-pyruvic transaminase, glutamic-oxalacetic transaminease, urea nitrogen, creatinine, blood glucose are in normal range (NR).
Routine urinalysis, stool routine situation of change before and after 6.4 test-meals: 100 subjects, routine urinalysis, stool routine inspection before and after test-meal
It looks into and is showed no exception.
6.5 efficiency index
6.5.1 serum total cholesterol
For serum total cholesterol with decreased significantly compared with itself before test-meal, difference has height after table 4,5 shows test-meal group test-meal
It spends conspicuousness (p < 0.01)；Test-meal group serum total cholesterol reduces after test-meal, and with control group comparison among groups, difference has height aobvious
Work property (P < 0.01).Illustrate that invention formulation plays the role of reducing human serum total cholesterol.
The serum total cholesterol variation of 4 test-meal of table front and back (mmol/L,
Note: * * P < 0.01, ## P < 0.01 compared with before this group of test-meal compared with the control group.
The decline of 5 serum total cholesterol of table is efficient
Note: * * P < 0.01 compared with the control group
6.5.2 serum triglyceride
By table 6,7 as it can be seen that serum levels of triglyceride is decreased obviously after test-meal group test-meal, and compared with itself, difference has before test-meal
Highly significant (P < 0.01), test-meal group serum triglyceride reduces after test-meal, and with control group comparison among groups, difference has height
Conspicuousness (P < 0.01).Illustrate that invention formulation has the function of reducing human serum triglyceride.
The serum triglyceride variation of 6 test-meal of table front and back (mmol/L,)
Note: * * P < 0.01, ## P < 0.01 compared with before this group of test-meal compared with the control group.
The decline of 7 serum triglyceride of table is efficient
Note: * * P < 0.01 compared with the control group
6.5.3 serum High Density Lipoprotein Cholesterol
By table 8,9 as it can be seen that serum High Density Lipoprotein Cholesterol is significantly raised after test-meal group test-meal, itself compare with before test-meal
There is conspicuousness (P < 0.01) compared with difference, test-meal group serum High Density Lipoprotein Cholesterol is significantly raised after test-meal, with control group group
Between compare, difference has conspicuousness (P < 0.01).
The serum High Density Lipoprotein Cholesterol variation of 8 test-meal of table front and back (mmol/L,)
9 serum High Density Lipoprotein Cholesterol of table increases efficient
Note: * * P < 0.05 compared with the control group
6.5.4 total effective rate
Test-meal group takes invention formulation 30 days, and reducing blood lipid total effective rate is 82.00%, compares with control group (16.00%)
Compared with difference has highly significant (P < 0.01).
10 rate and blood-lipid decreased total effective rate of table
Note: * * P < 0.01 compared with the control group.
7. brief summary
Using blind itself and two kinds of control designs of placebo.Meet the simple dyslipidemia for the standard of being included in certainly for 100
It is willing to subject, is randomly divided into two groups, test-meal group 50, control group 50 by blood lipid level substantially equilibrium.Two groups are taken this respectively
Invention preparation and placebo, 3 tablets each time, 3 times a day.Original life and eating habit are kept during observation.Knot is tested after 30 days
Beam, the results showed that invention formulation can be substantially reduced dyslipidemia crowd serum total cholesterol and triglycerides (P < 0.01),
High-density lipoprotein cholesterol apparent increase (P < 0.01) after test-meal.Blood, urine, feces are conventional before and after test-meal, liver, kidney function, blood glucose etc.
Every Testing index does not find any toxic side effect in normal range (NR), with good prevention and treatment cardiovascular and cerebrovascular disease
Function.
Claims (2)
1. a kind of preparation for protecting liver, adjusting blood lipid, using 400~500 parts of pueraria lobata, 400~500 parts of Radix Glycyrrhizae, cape jasmine
300~400 parts, 30~400 parts of Radix Salviae Miltiorrhizae, 60~120 parts of Radix Notoginseng, 40~70 parts of propolis, 30~70 parts of dextrin extracted, mixing,
Then through particle preparation, pack be made granule or it is filled capsule is made, tablet is made in tabletting.
2. a kind of preparation for protecting liver, adjusting blood lipid according to claim 1, it is characterised in that preparation process is
Pueraria lobata, Radix Glycyrrhizae, cape jasmine, the Radix Salviae Miltiorrhizae of formula ratio is taken to be placed in multi-function extractor, the water of 8 times of dosing material amounts impregnates 30 minutes, adds
Thermal extraction 2 times, 1.5 hours every time, filtering, filtrate stood 12 hours, took supernatant, is squeezed and is filtered with plate and frame filter press, collected
Filtrate is set in vacuum concentration pot, and being concentrated into relative density is 1.06-1.10, obtains extractum A；Take the propolis of formula ratio set -4 DEG C with
After being freezed in lower household freezer, it crushed 20 meshes and obtain coarse powder, set in percolating extractor, add 95% ethyl alcohol dipped powder about 3cm,
After infiltration 24 hours, equipment, coutroi velocity 0.15L/min are opened, and supplement 95% ethyl alcohol from above at any time, keeps extracting liquid level
Higher than 3~4cm of propolis face, when the volume of percolate is equivalent to 8 times of crude drug weight, collection percolate, percolate is stood
After sedimentation 12 hours, supernatant centrifugation removes lead, the percolate after except lead is recycled ethyl alcohol using decompression method, and be concentrated into phase
Medicinal extract B is obtained to density 1.06~1.10；Merge extractum A and B, vacuum drying obtains dry extract, crushing sieves with 100 mesh sieve；By Radix Notoginseng powder
It is broken to sieve with 100 mesh sieve, it is mixed together with extract powder and dextrin, granule then is made through particle preparation or filled glue is made
Tablet is made in wafer, tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310054324.9A CN103110718B (en) | 2013-02-03 | 2013-02-03 | A kind of preparation for protecting liver, adjusting blood lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310054324.9A CN103110718B (en) | 2013-02-03 | 2013-02-03 | A kind of preparation for protecting liver, adjusting blood lipid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103110718A CN103110718A (en) | 2013-05-22 |
| CN103110718B true CN103110718B (en) | 2019-05-14 |
Family
ID=48409121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310054324.9A Active CN103110718B (en) | 2013-02-03 | 2013-02-03 | A kind of preparation for protecting liver, adjusting blood lipid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103110718B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104855762A (en) * | 2015-04-30 | 2015-08-26 | 江苏江大源生态生物科技有限公司 | Compound bee product and preparation method thereof |
| CN108324921B (en) * | 2018-05-18 | 2021-02-19 | 宁波御坊堂生物科技有限公司 | A pharmaceutical composition with cyst removing and gastric mucosa protecting effects, and its preparation method |
| CN111671792B (en) * | 2020-06-28 | 2022-05-17 | 瑞普（天津）生物药业有限公司 | Traditional Chinese medicine composition for preventing and treating liver injury and preparation method thereof |
| CN115487268B (en) * | 2022-09-30 | 2024-03-08 | 广州聚缘堂丹道药业科技有限公司 | Composition for promoting blood circulation and toxin metabolism and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244123A (en) * | 2008-02-25 | 2008-08-20 | 药都制药集团股份有限公司 | Novel technique for preparing pseudo-ginseng red sage root lozenge |
| CN101564419A (en) * | 2008-04-23 | 2009-10-28 | 北京卓越同创药物研究院 | Medicinal composition for protecting liver |
-
2013
- 2013-02-03 CN CN201310054324.9A patent/CN103110718B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244123A (en) * | 2008-02-25 | 2008-08-20 | 药都制药集团股份有限公司 | Novel technique for preparing pseudo-ginseng red sage root lozenge |
| CN101564419A (en) * | 2008-04-23 | 2009-10-28 | 北京卓越同创药物研究院 | Medicinal composition for protecting liver |
Non-Patent Citations (4)
| Title |
|---|
| 松花粉对酒精性肝损伤的保护功能研究;谢惠萍等;《中国现代医药杂志》;20080430;第10卷(第4期);第47-49页 |
| 栀子黄色素对四氯化碳肝损伤小鼠的影响;张德权等;《营养学报》;20021231;第24卷(第3期);第269-273页，尤其是第272页左栏第1段 |
| 颐甘胶囊;3721健康网;《http://www.jk3721.com/html/yaopinzhishi/yaopinshuomingshu/200905/16-4714.html》;20090516;第1页【颐甘胶囊保健功能】第2-3行 |
| 黄芪多糖咀嚼片降血脂人体试食试验研究;昭日格图等;《食品科学》;20091231;第30卷(第15期);第196-199页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103110718A (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103652552B (en) | Functional food with effects of reducing lipid and preventing fatty liver | |
| CN102048959A (en) | Dendrobium candidum compound preparation capable of regulating function of human body in two-way manner and preparation method thereof | |
| CN103110718B (en) | A kind of preparation for protecting liver, adjusting blood lipid | |
| CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
| CN102836379A (en) | Traditional Chinese medicine compound preparation for reducing lipid and dispelling effects of alcohol as well as preparation method and application of same | |
| CN108837036A (en) | A kind of blood fat-reducing blood pressure-decreasing, the preparation for preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN1226940C (en) | Royal jelly composition with improved sleep function | |
| CN104815166B (en) | A kind of Chinese medicine composition for treating diabetes and its preparation and application | |
| CN103784934B (en) | A kind of pharmaceutical composition and application thereof preventing and treating acute myocardial infarction | |
| CN103054906B (en) | Propolis ethanol extract for alleviating hangover and preparation method thereof, and application of propolis ethanol extract in producing buccal tablets | |
| CN105832877B (en) | A kind of health care product and its preparation method and application with liver-protecting efficacy | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN107537028A (en) | A kind of while auxiliary hyperglycemic and the formula of hypotensive and preparation method thereof | |
| KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
| CN112022939A (en) | Capsule for treating hypertension complicated with hyperlipidemia and preparation method thereof | |
| CN100333767C (en) | Medicine for treating male infertility | |
| CN101642541B (en) | Composition with hepatoprotective effect, preparation method and application thereof | |
| CN1602926A (en) | Kudzuvine root containing capsule capable of regulating blood pressure and blood fat, preventing and treating cardiovascular and cerebrovascular diseases | |
| CN110506822A (en) | A kind of rhizoma polygonati Poria cocos teabag drink and preparation method thereof | |
| CN110038043A (en) | A kind of pueraria lobata toxin expelling nutrient powder and its preparation method and application | |
| CN106619972A (en) | Hirsutella hepiali chen et shen mycelium powder hypoglycemic capsule and preparation method and application thereof | |
| CN104127545B (en) | New application of murraya tetramera huang and extract thereof in preparation of medicines | |
| WO2018192147A1 (en) | Heart-nourishing and health-preserving tea and preparation method therefor | |
| CN108208781A (en) | A kind of reparation hepatic injury, the Cordyceps militaris composition and preparation method and application of strengthen immunity | |
| CN101129430A (en) | Traditional Chinese medicine composition used for preventing and controlling cardiovascular disease, processes for producing same and application of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |